Lupin completed acquisition of GAVIS Pharma

Posted on:10 Mar 2016 14:06:22
Lupin completed acquisition of GAVIS Pharma
10 March 2016 Current Affairs: Drug major Lupin Announced completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS). Lupin had announced the acquisition on July 23, 2015. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products. GAVIS' New-Jersey based manufacturing facility will become Lupin's first manufacturing site in the US. GAVIS is a privately held company, specialising in formulation development, manufacturing, packaging, sales, marketing and distribution of pharmaceutical products. It has 62 abbreviated new drug application (ANDA) filings pending approval with the US FDA and a pipeline of over 65 plus products under development GAVIS' pending approvals address a market of over USD 9 billion. The combined company will have a portfolio of over 120 in-market products, more than 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with US FDA, catering to a USD 63.8-billion market. Lupin shares were trading 0.33 per cent up at Rs 1,822.75 during the afternoon session on BSE.
Drug major Lupin Announced completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS). Lupin had announced the acquisition on July 23, 2015. GAVIS brings to Lupin a highly skilled US-based manufacturing and research organisation which would complement its Florida-based R&D centre for inhalation products. GAVIS' New-Jersey based manufacturing facility will become Lupin's first manufacturing site in the US. GAVIS is a privately held company, specialising in formulation development, manufacturing, packaging, sales, marketing and distribution of pharmaceutical products. It has 62 abbreviated new drug application (ANDA) filings pending approval with the US FDA and a pipeline of over 65 plus products under development GAVIS' pending approvals address a market of over USD 9 billion. The combined company will have a portfolio of over 120 in-market products, more than 185 cumulative filings pending approval and a deep pipeline of products under development for the US. The acquisition creates the 5th largest pipeline of ANDA filings with US FDA, catering to a USD 63.8-billion market. Lupin shares were trading 0.33 per cent up at Rs 1,822.75 during the afternoon session on BSE.

Monthly Current Affairs

Fresherslive telegram Group

Current Affairs Section

Daily Current Affairs Quiz


Daily Current Affairs Videos Video Link
15th June 2019 Current Affairs Video
14th June 2019 Current Affairs Video
13th June 2019 Current Affairs Video
12th June 2019 Current Affairs Video
11th June 2019 Current Affairs Video
Watch more Current Affairs Videos





Subscribe to Current Affairs

Enter your email to get daily current affairs
SUBSCRIBE
Download Current Affairs PDF
Weekly pdf's
60 24
at 36 off

Monthly pdf's
250 89
at 161 off

Yearly pdf's
1200 499
at 701 off

YEARLY Current Affairs PDF

  • Yearly Current Affairs 2018 PDF


  • Currentt Affairs 2019 June

    17 JUNE
    NEWS
    16 JUNE
    NEWS
    15 JUNE
    NEWS
    14 JUNE
    NEWS

    Currentt Affairs 2019 May

    31 MAY
    NEWS
    30 MAY
    NEWS
    29 MAY
    NEWS
    28 MAY
    NEWS

    Currentt Affairs 2019 April

    30 APRIL
    NEWS
    29 APRIL
    NEWS
    28 APRIL
    NEWS
    27 APRIL
    NEWS




    Crack All Competitive Exams without Coaching - Buy Our PDF's @ Rs. 24/- only
    BUY NOW
    ×